Platinum

What is Platinum?

In 1945 Hunter, Milton and Perry reported in the British Journal of Industrial Medicine that 52 of 91 men exposed to complex platinum salts had developed a respiratory illness: runny nose, sneezing, chest tightness, wheezing, shortness of breath and, in some, cyanosis. Thirteen men also complained of dermatitis. The same report recorded a finding that still holds: men exposed to much higher airborne concentrations of metallic platinum did not get sick.

Platinum (Pt, element 78, atomic weight 195.084) is a dense, gray-white noble metal, 21.45 grams per cubic centimeter, melting at 1,768 °C. It resists corrosion and stomach acid as the bare metal, which is why it sits in jewelry, pacemaker leads, dental alloys and many car catalytic converters. Its biology depends largely on what it is bonded to. Bonded to six chlorine atoms, it causes occupational asthma at airborne levels measured in billionths of a gram per cubic meter. Bonded to two ammonia groups and two chlorides in a particular geometry, it is cisplatin, a cancer drug. Divided into nanometer-scale particles and suspended in water, it is what a "colloidal platinum" or "nano platinum" bottle says it contains.

This issue treats platinum as a substance nobody should be drinking, and keeps those chemical forms apart, because the hazard and the evidence attach to the form.

Common Names

• Platinum, Pt, element 78; homeopathic Platinum metallicum

• Colloidal platinum, platinum hydrosol, nano platinum, platinum nanoparticles (PtNPs), platinum nanocolloid (Pt-nc), "mesoplatinum", "monatomic" or "ionic" platinum, platinum water

• PAPLAL, a Japanese mixture of platinum and palladium nanoparticles

• Chloroplatinates (complex halogenated platinum salts): hexachloroplatinic acid (chloroplatinic acid, H2PtCl6), ammonium hexachloroplatinate, sodium hexachloroplatinate, potassium tetrachloroplatinate

• Other platinum salts: platinum(IV) chloride (PtCl4), platinum(II) chloride (PtCl2), platinum sulfate, platinum dioxide (Adams' catalyst), tetraammine platinum dichloride

• Platinum drugs: cisplatin (Platinol), carboplatin (Paraplatin), oxaliplatin (Eloxatin)

Primary Active Compounds

• Platinum(0), the metal. Bulk metal, foil, sponge, catalyst powder and nanoparticles. The WHO's Environmental Health Criteria 125 (1991) states that "metallic platinum seems to be non-allergenic."

• Chloroplatinates. Platinum(IV) or platinum(II) with four or six chloride ligands. Water-soluble, reactive, and the cause of platinum salt sensitivity, the modern name for the disease once called platinosis.

• Non-halogenated soluble salts. Tetraammine platinum dichloride is the documented example of a soluble platinum compound that did not sensitize workers over 20 years of surveillance.

• Platinum coordination drugs. Cisplatin, carboplatin and oxaliplatin, given intravenously under oncology supervision. Context only in this issue.

• Released platinum ions. Laboratory work on metallic nanoparticles shows that small amounts of soluble platinum species form when particles sit in cell culture medium, which matters for what a "metal only" colloid actually delivers.

Key Note

No nutrition authority treats platinum as essential. The US Food and Nutrition Board lists no RDA, AI or UL for platinum, and platinum is absent from Annex I of EU Directive 2002/46/EC, the list of minerals permitted in food supplements. No controlled human trial of any colloidal or nano platinum product taken by mouth turned up in this issue's searches of PubMed and the wider literature.

The documented human story of platinum is a story of workers who breathed its salts, many of whom did not fully recover after they stopped.

Scan any Platinum product in seconds with the free NutrientWise app: App Store · Google Play

Primary Functions & Benefits

Platinum has no known role in human physiology, no deficiency disease, and no demonstrated benefit from any form taken by mouth. What follows is the laboratory record that colloidal platinum marketing draws on, reported with the model, the preparation and the dose route, because none of it was done in people.

The antioxidant claim, where it comes from

• Test tube. Kajita and colleagues (Free Radical Research, 2007) made pectin-stabilized platinum particles averaging 4.7 nanometers and showed they quenched superoxide and broke down hydrogen peroxide like the enzymes superoxide dismutase and catalase. That is a chemistry result in solution, not an effect in a body.

• Worms. Kim and colleagues (Mechanisms of Ageing and Development, 2008) reported that 0.5 millimolar nano platinum extended the lifespan of the nematode Caenorhabditis elegans. A 2010 follow-up used particles conjugated to an HIV-derived cell-penetrating peptide to extend lifespan by 21 percent in normal worms.

• Mice, liver. Choi and colleagues (2015) reported that a platinum nanocolloid reduced liver lipid peroxidation and carbon tetrachloride damage in mice and concluded it "may have a potential to be used as an antioxidant supplement." Katsumi and colleagues (Metallomics, 2014) protected mouse livers from ischemia and reperfusion injury with citrate-coated particles of 30 and 106 nanometers, given by intravenous injection.

• Mice, colitis. Zhu and colleagues (International Journal of Nanomedicine, 2019) gave 5, 30 and 70 nanometer particles by stomach tube for 8 days to mice with chemically induced colitis. Colitis scores improved, and the same particles caused gut dysbiosis, unfavorably altering microbial diversity and the Firmicutes to Bacteroidetes ratio.

The gap between those studies and a bottle

Each favorable finding above used a specific laboratory particle with a stated size and coating, in a solution, a worm or a rodent, often by injection. None tested a retail colloid, none measured a human outcome, and the Katsumi liver protection results came from intravenous dosing that a drinker never receives.

Forms & Standardization

For platinum this section is the toxicology of each chemical form, because the form decides whether the substance is close to inert or a sensitizer. No supplement form has an official purity, particle size or concentration standard.

How much the form matters, in one table of rat data

The WHO's Environmental Health Criteria 125 (1991) lists oral LD50 values in rats (the dose that kills half the animals) that span more than two orders of magnitude across platinum compounds:

• Sodium hexachloroplatinate, Na2[PtCl6]: 25 to 50 mg per kg

• Ammonium hexachloroplatinate, (NH4)2[PtCl6]: 195 to 200 mg per kg

• Platinum(IV) chloride, PtCl4: 240 mg per kg

• Platinum sulfate tetrahydrate: 1,010 mg per kg

• Platinum(II) chloride, PtCl2: above 2,000 mg per kg, no LD50 calculable

• Platinum dioxide, PtO2: above 8,000 mg per kg, no LD50 calculable

The document's summary line is that "soluble platinum compounds are much more toxic than insoluble ones." These are lethality figures in animals, cited to show the spread between forms, not as any guide to human intake.

Metallic platinum (bulk, sponge, powder)

The metal is poorly absorbed (CDC's biomonitoring summary puts uptake of the metal and insoluble salts below 1 percent of a dose) and is the form EHC 125 calls apparently non-allergenic. Ten days after inhalation exposure in experimental animals, whole-body retention of platinum metal was about 6 percent. EHC 125 records only one reported case of an alleged contact dermatitis from a "platinum" ring, a contrast with nickel, the common culprit.

Chloroplatinates (complex halogenated salts)

Hexachloroplatinic acid, its sodium, potassium and ammonium salts, and the tetrachloroplatinates are the compounds behind platinum salt sensitivity. They are used in refining, in making automotive catalysts, and as starting materials for platinum drugs. A 2013 German case report (Thanasias and colleagues) describes a 22-year-old worker making cytotoxic drugs who developed asthma about a year after starting work with potassium tetrachloroplatinate, the only platinum salt he handled, confirmed by a positive inhalation challenge.

Tetraammine platinum dichloride, the counterexample

Linnett and Hughes (Occupational and Environmental Medicine, 1999) analyzed 20 years of air sampling and medical surveillance from three operations handling soluble platinum compounds (the lead author was at Johnson Matthey). Among workers consistently exposed to chemical processes, the estimated cumulative chance of sensitization after 5 years was 51 percent with chloroplatinate exposure, 33 percent with mixed exposure, and 0 percent with tetraammine platinum dichloride alone, at comparable airborne levels of soluble platinum. The authors attributed the difference to the chemical stability of the ammine compound and argued that limits should follow the specific compound, not "soluble platinum" generically.

Platinum nanoparticles and "colloidal" platinum

Particle size changes the toxicology:

• Yamagishi and colleagues (Nanoscale Research Letters, 2013) injected mice with platinum particles under 1 nanometer. A single intravenous dose caused necrosis of kidney tubule cells and urinary casts, with dose-dependent rises in blood urea nitrogen; four weeks of twice-weekly intraperitoneal dosing caused tubular atrophy and inflammation. Particles of 8 nanometers did not.

• Isoda and colleagues (Pharmazie, 2017) found that 1 nanometer particles given intravenously raised liver enzymes and blood urea nitrogen and induced IL-6 and IL-1 beta, while 8 nanometer particles had no effect even at 20 mg per kg.

• Lin and colleagues (International Journal of Nanomedicine, 2019) gave 5 and 70 nanometer particles intravenously at 3 to 10 mg per kg and saw dose-dependent slowing of heart rate and complete atrioventricular block at the higher doses.

• Brown and colleagues (Nanomaterials, 2018) found that 2 to 4 nanometer platinum cores packaged in roughly 70 nanometer PEG-lipid micelles were tolerated at up to 15 mg platinum per kg intravenously, with normal blood chemistry and organ histology three weeks later, while still noting accumulation in clearance organs.

• Pelka and colleagues (Chemical Research in Toxicology, 2009) showed platinum particles entering human colon carcinoma cells, lowering glutathione and breaking DNA strands, worst at the smallest size. The follow-up (Gehrke and colleagues, Archives of Toxicology, 2011) found platinum bound to cellular DNA and concluded the strand breaks were most likely caused by platinum ions forming from the metallic particles.

• Katao and colleagues (Experimental Animals, 2011) gave platinum particles to rats by stomach tube and found 18 genes altered across 12 of 25 tissues examined, with inflammation-related genes changed in the glandular stomach; the authors judged the overall effect on systemic gene expression not marked.

• Manzoor and colleagues (Biological Trace Element Research, 2025) gave rats platinum particles of several sizes and shapes by mouth for 28 days. The rats became weak and lost weight steadily, with oxidative-stress markers, inflammatory cytokines and tissue damage in the lungs.

Retail colloids rarely state the size distribution, the coating, or how much dissolved platinum is present, which are exactly the variables that separated harm from no harm in these studies.

PAPLAL (platinum and palladium nanoparticles)

A Japanese mixture used mainly on skin. The research group studying it (Shibuya and colleagues, PLoS One, 2014) states it has been used in Japan "to treat chronic diseases over the past 60 years," and its published work is in mice, cultured cells and human skin patch tests, not oral trials.

Platinum drugs (context only)

Cisplatin, approved by the US FDA in 1978, carboplatin (1989) and oxaliplatin (2002) are platinum coordination complexes given by intravenous infusion for cancer. They trace back to Barnett Rosenberg's 1965 Nature paper showing that electrolysis products from a platinum electrode stopped Escherichia coli from dividing. The International Agency for Research on Cancer classified cisplatin as probably carcinogenic to humans (Group 2A) in 1987. Their adverse-effect profiles are covered in Section 12 and their interactions in Section 17.

Food Sources

Platinum is not a food nutrient, so this section covers routes of exposure. None of them creates a need for supplementation, and most of the research on them is about keeping exposure down.

Diet

Food carries traces measured in nanograms (billionths of a gram) per kilogram. A preliminary 2006 study in Pure and Applied Chemistry ("Uptake of platinum-group elements with the diet") reported mean platinum of about 83 nanograms per kilogram in full-cream and skim milk, 171 in wholemeal bread and 257 in white bread. The authors concluded that diet contributes a significant share of total exposure to the platinum-group metals, but published estimates of daily dietary intake are sparse and this issue found no national total diet study that reports one.

Traffic and catalytic converters

Catalytic converters shed small amounts of platinum into road dust and soil. EHC 125 cited emissions of about 2 to 39 nanograms per kilometer for monolith-type catalysts, against 0.8 to 1.9 micrograms per kilometer for the older pellet type. CDC's biomonitoring summary states that ambient air levels from converters are "thousands of times lower than occupational exposure limits," and the German Human Biomonitoring Commission found no proven influence of traffic emissions on internal platinum levels.

Dental alloys

For many adults the main everyday source is dental work. Precious-metal dental alloys can contain up to 17 percent platinum. In the German Environmental Survey of 1998 (1,080 adults aged 18 to 69), median urinary platinum was about 1.3 to 1.5 nanograms per liter in people without such dental work and rose to 4.9 with increasing numbers of inlays and crowns. CDC's summary describes dental restorations raising urinary platinum five to twelve-fold. The German commission set a reference value of 10 nanograms per liter of urine for adults without precious-metal dental work.

Background levels in people

US national biomonitoring found urinary platinum below the limits of detection (0.009 to 0.07 micrograms per liter) in the general population. EHC 125 reported blood levels of 0.1 to 2.8 micrograms per liter in the general population.

Occupational exposure

Refinery and precious-metal workers have urinary platinum about 1,000 times general population levels, according to CDC. Pharmacy and hospital staff who handle cisplatin and carboplatin show elevations of ten-fold or less.

Medical sources

Cancer patients receiving platinum drugs get by far the highest doses of any group. Silicone breast implants contain platinum catalyst residue; FDA concluded that the small amounts reaching nearby tissue are in the zero oxidation state, "would pose the lowest risk," and "do not represent a significant risk."

Bottom line on exposure

The body absorbs less than 1 percent of swallowed metallic or insoluble platinum. There is no dietary shortfall to fix.

Who Should Take Platinum

No one should take platinum in any form as a supplement. There is no deficiency to correct, no human trial showing benefit, and the only well-characterized human effects of platinum compounds outside cancer treatment are harmful.

Who is unavoidably exposed

• Workers in precious metal refineries, catalyst production plants and platinum chemical manufacture, especially anyone handling hexachloroplatinic acid or chloroplatinate salts.

• Workers producing platinum cancer drugs, who may handle tetrachloroplatinate starting materials.

• Pharmacy, nursing and hospital staff preparing or giving cisplatin, carboplatin or oxaliplatin.

• Cancer patients receiving those drugs.

• People with precious-metal dental work, at low and stable levels.

Who should consider testing

• Refinery and catalyst workers: skin prick testing with hexachloroplatinate is the standard surveillance tool. In the South African refinery cohort of Calverley and colleagues (1995), a positive platinum salt skin prick test had a 100 percent positive predictive value for symptoms and signs of platinum salt sensitivity if exposure continued. Merget and colleagues (2016) recommend removal from exposure immediately after a positive skin prick test, whether or not symptoms are present.

• Blood or urine platinum is not a substitute. In a small 2002 case series, Merget and colleagues found serum platinum in catalyst workers neither sensitive nor specific for predicting sensitization, partly because dental alloys raised levels in people with little occupational exposure.

• Anyone who has been drinking a platinum colloid and develops new rhinitis, wheezing, hives or unexplained kidney test changes should tell a clinician exactly what product they used. No validated test exists for "platinum load" from supplements.

Who Should AVOID or Use Caution

Contraindications

• Anyone diagnosed with platinum salt sensitivity, occupational asthma from platinum salts, or a hypersensitivity reaction to cisplatin, carboplatin or oxaliplatin.

• Anyone currently receiving platinum chemotherapy. In mice, injected 1 nanometer platinum particles made cisplatin toxicity worse (Isoda and colleagues, 2017).

• Pregnancy and breastfeeding. A 2019 review of platinum nanoparticle toxicity by Czubacka and Czerczak of the Nofer Institute of Occupational Medicine reported that animal studies found no fetal or maternal toxicity but did find increased mortality and decreased growth in offspring. EHC 125 likewise records reduced offspring weight in mice given platinum sulfate. This issue found no human pregnancy data.

• Children.

Use Caution

• Smokers. In Calverley's refinery cohort the risk of sensitization was about eight times higher in smokers than in non-smokers; in Merget's 2000 catalyst cohort, smoking carried a relative risk of 3.9 among highly exposed workers.

• People with asthma or chronic kidney disease, two of the organ systems where platinum salts and small platinum particles have caused harm.

• People with hearing loss or neuropathy from previous platinum chemotherapy.

Critical Safety Point

Platinum salt asthma usually persists once established. In Merget and colleagues' 1994 study of 24 refinery workers with confirmed platinum salt asthma, 17 still reported asthma after 19 months (range 1 to 77) away from exposure, and bronchial responsiveness to both methacholine and platinum salt did not decrease. This issue found no study testing whether drinking platinum colloids can sensitize, and that absence of data is not a safety finding.

Recommended Dosages

There is no recommended dose of platinum for any person, by any route, in any form. The numbers below are regulatory ceilings for air in workplaces. None is an amount to consume.

Soluble platinum salts (as Pt)

• OSHA permissible exposure limit: 0.002 mg per cubic meter, 8-hour time-weighted average (29 CFR 1910.1000, Table Z-1).

• NIOSH recommended exposure limit: 0.002 mg per cubic meter, up to 10-hour time-weighted average.

• ACGIH threshold limit value: 0.002 mg per cubic meter, first set by ACGIH in 1963 on limited air sampling data, according to Smit and colleagues (2023).

• NIOSH immediately dangerous to life or health (IDLH): 4 mg per cubic meter. NIOSH states this figure is 2,000 times the REL, chosen as a respirator protection factor, and that it "cannot be set to protect" already sensitized individuals.

• The Health Council of the Netherlands' expert committee (DECOS), 2008: a recommended health-based limit of 5 nanograms per cubic meter, 400 times lower than the US figure, based mainly on Merget's catalyst cohort.

Platinum metal

• NIOSH REL and ACGIH TLV: 1 mg per cubic meter.

• OSHA: no current limit; its chemical database lists the metal's PEL as "not established." OSHA's 1989 rule had adopted 1 mg per cubic meter, but NIOSH notes that rulemaking was remanded by the US Circuit Court of Appeals and the limit is not in force.

Dietary reference values

• No RDA, AI or Tolerable Upper Intake Level exists for platinum, and the EU permits no platinum compound in food supplements under Directive 2002/46/EC.

Duration

Not applicable. There is no duration of use for a substance with no recommended dose.

Timing & Administration

Not applicable: there is no correct time or way to take platinum. What can be said is what happens to swallowed platinum, which is the opposite of what "bioavailable" marketing implies.

What the body does with swallowed platinum

• In rats given radiolabeled platinum(IV) chloride by mouth, less than 1 percent of the dose remained in the whole body after 3 days (EHC 125). Most of it passed straight through the gut.

• Swallowed platinum cleared from the airways was excreted in feces with a half-time of about 24 hours in the same body of animal work.

• Insoluble platinum dioxide fed to rats over 4 weeks (4,308 mg in total per rat) was "only taken up in minute amounts."

• What is absorbed concentrates mainly in the kidneys, liver, spleen and adrenals, and is excreted in urine. After intravenous platinum(IV) chloride, rats still retained about 14 percent of the dose at 28 days.

What is known about clearance of colloids

This issue found no published pharmacokinetic study of any retail platinum colloid in humans, so any claim about how fast a product's particles leave the body has no human data behind it. Injected platinum nanoparticles in mice accumulated in the liver and spleen in the studies cited in Section 4.

Timeline of Effects

There is no timeline of benefit, because no benefit has been shown. The timelines that are documented are for harm, from occupational and clinical records, and they are given here so a reader can recognize them, not as a guide to use.

Sensitization to platinum salts

• Calverley and colleagues (Occupational and Environmental Medicine, 1995) followed 78 new recruits at a South African refinery. After 24 months, 32 (41 percent) had been diagnosed with platinum salt sensitivity and medically separated: 22 confirmed by skin prick test and 10 symptomatic but skin test negative.

• In Smit and colleagues' 2025 cohort of 1,614 new refinery hires, median time to sensitization was 1.9 years, at an incidence of 1.48 cases per 100 person-years.

• In Merget's 5-year catalyst plant cohort (2000), highly exposed new employees converted to a positive skin test at 5.9 per 100 person-years, against 2.1 for those already employed at the start.

After exposure stops

• Merget and colleagues (1999): of 74 workers with platinum salt asthma who had been transferred to other work areas or had left the plant, 37 (50 percent) still reported asthma symptoms a median 54 months after transfer.

• Merget and colleagues (2016): in 96 workers re-examined a median 67 months after diagnosis, skin test positivity fell from 86 to 52 percent and rhinitis, conjunctivitis and hives improved, but 77 percent still had asthma and 86 percent still had airway obstruction or bronchial hyperresponsiveness.

Platinum drug reactions (clinical context)

Carboplatin allergy is also a delayed-onset problem. Markman and colleagues (Journal of Clinical Oncology, 1999) found that 24 of 205 patients (12 percent) treated at the Cleveland Clinic developed a carboplatin hypersensitivity reaction, after a median of 8 platinum courses (range 6 to 21).

What a fair trial of a colloid would be

None is defined. No human trial exists from which to borrow a duration, and the occupational record shows that sensitization commonly appears within the first two years of exposure, not the first two weeks.

Benefits of Taking Platinum

There are no documented benefits of taking platinum as a supplement. What follows is history, not evidence of benefit.

How platinum reached the clinic

In 1965 the Michigan State University biophysicist Barnett Rosenberg, with Van Camp and Krigas, reported in Nature that electrolysis products from a platinum electrode inhibited cell division in E. coli. That accident led to cisplatin and its successors, which are infused cancer drugs, toxic by design and dosed by oncologists. Their story is a reason to respect platinum chemistry, not evidence that platinum is good to swallow.

How platinum reached the supplement shelf

Colloids such as MesoPlatinum were already on sale in the US by the late 2000s. Much of the early antioxidant work came from Japanese groups at the University of Tokyo (Kajita and colleagues, 2007) and the Prefectural University of Hiroshima (Saitoh, Miwa and colleagues, from 2009), in cultured cells, worms and mice. Interest in platinum for oxidative stress grew out of test-tube enzyme-mimic findings, not from any observation of benefit in people.

Potential Negatives & Side Effects

These are organized by form, because no single list applies to all platinum.

Chloroplatinate salts (occupational, inhaled or on skin)

• Rhinitis, sneezing, conjunctivitis, chest tightness, wheezing, cough, shortness of breath and asthma.

• Contact urticaria (hives) and allergic skin reactions; in Hunter's 1945 group, 13 men complained of dermatitis.

• Rising total IgE. In the South African cohort (Calverley and colleagues, Clinical and Experimental Allergy, 1999), the likelihood of a rise in total IgE was nine times greater in workers who became sensitized.

• NIOSH lists eye and nose irritation, cyanosis, dermatitis, skin sensitization and lymphocytosis among the symptoms of soluble salt exposure.

Platinum nanoparticles (animal and cell evidence only)

• Kidney tubule necrosis and liver enzyme rises in mice from injected particles of about 1 nanometer or smaller.

• Heart rate slowing and complete atrioventricular block in mice from injected 5 and 70 nanometer particles.

• Gut dysbiosis in mice given particles by stomach tube, and weight loss with lung injury in rats dosed by mouth for 28 days (Manzoor and colleagues, 2025).

• Slowed growth and increased cell death in normal human esophageal lining cells exposed to platinum nanocolloid (Li and colleagues, Journal of Nanoscience and Nanotechnology, 2016).

• Lung inflammation and raised serum IgE in mice after particles were placed directly into the windpipe (Park and colleagues, Archives of Pharmacal Research, 2010).

• DNA strand breaks in human colon cancer cells; cytotoxicity and genotoxicity in mouse fibroblasts and macrophages (Hashimoto and colleagues, 2015).

• Hatching delay and slowed heart rate in zebrafish embryos exposed to 3 to 10 nanometer particles (Asharani and colleagues, Nanotoxicology, 2011); silver particles in the same tests were more toxic and gold particles showed no toxicity.

Platinum drugs (clinical context, intravenous)

• Cisplatin: renal toxicity in 28 to 36 percent of patients after a single 50 mg per square meter dose, ototoxicity in up to 31 percent, hearing loss in an estimated 40 to 60 percent of children, myelosuppression in 25 to 30 percent, and nausea and vomiting in almost all patients, according to its US label.

• Oxaliplatin: grade 3 sensory neuropathy in 12.4 percent of patients on the oxaliplatin combination during treatment in the 2,246-patient MOSAIC adjuvant colon cancer trial, with 1.1 percent still at grade 3 a year later; milder neuropathy was more common.

• Carboplatin: hypersensitivity in 12 percent of 205 patients in the Cleveland Clinic series.

Deficiency Symptoms

No platinum deficiency state exists in humans or animals.

What platinum addresses

Nothing that is lacking. Contrast a genuine trace element: selenium deficiency causes Keshan disease, a cardiomyopathy described in a selenium-poor region of China and prevented by selenium supplementation. No comparable disease, biomarker or population-level shortfall has ever been described for platinum, and no tissue has been shown to require it.

Bottom line

A product that implies platinum "replenishes" or "restores" something is describing a deficiency that has never been documented.

Toxicity Symptoms

At high intake

• Inhaled chloroplatinate salts, in sensitized workers: immediate-type reactions with runny nose, sneezing, watery eyes, chest tightness, wheeze, breathlessness and, in severe cases described by Hunter in 1945, cyanosis. NIOSH notes that exposure slightly above the 0.002 mg per cubic meter limit can provoke allergic reactions in sensitized workers.

• A swallowed soluble platinum salt, in a person: a 31-year-old man who drank photographic toning solution containing potassium chloroplatinite (potassium tetrachloroplatinate) in a suicide attempt developed acute oliguric kidney failure, metabolic acidosis, rhabdomyolysis and gastroenteritis, and recovered over a six-day hospital stay (Woolf and Ebert, Journal of Toxicology: Clinical Toxicology, 1991).

• Swallowed soluble platinum salts, in animals: acute lethality at tens to hundreds of mg per kg for the chloroplatinates (EHC 125). Rats drinking water containing platinum(IV) chloride at 182 mg per liter for 4 weeks kept normal weight gain; at three times the platinum concentration, weight gain fell about 20 percent in the first week.

• Injected nanoparticles, in mice: acute kidney injury from particles of about 1 nanometer, liver enzyme rises, and conduction block in the heart at 3 to 10 mg per kg.

• Platinum drugs, at therapeutic doses: kidney damage, hearing loss, nerve damage, bone marrow suppression and anaphylactic-type reactions.

Signs to reduce or stop

Stop any platinum colloid immediately, and see a clinician, if any of these appear:

• New nasal congestion, sneezing, itchy eyes, cough or wheeze, particularly if it worsens with each exposure.

• Hives, facial swelling or skin rash.

• Reduced urine output, swelling, or a rise in creatinine or blood urea nitrogen on routine blood work.

• Palpitations, fainting or a slow pulse.

General note

The toxic dose of a platinum compound depends on its ligands, its solubility and, for particles, its size. A label that says only "platinum" gives no basis for judging any of those.

How Platinum Works

Platinum compounds act through three different mechanisms, depending on form.

Haptens and IgE (chloroplatinates)

Chloroplatinates are small, reactive ions. Their chloride ligands can be displaced, letting the platinum bind to the body's own proteins. That protein and platinum complex is what the immune system recognizes. Smit and colleagues (2023) describe the salts as low molecular weight sensitizers that act as haptens, binding endogenous proteins and triggering a Type I (IgE-mediated) hypersensitivity reaction. Raulf-Heimsoth and colleagues (European Respiratory Journal, 2000) found that 17 sensitized workers with platinum salt asthma had significantly higher frequencies of particular T-cell receptor families than 15 unexposed controls, and that sodium hexachloroplatinate stimulated lymphocytes in vitro. Compounds whose ligands do not leave easily, like tetraammine platinum dichloride, did not sensitize in the Linnett and Hughes data, which is strong human evidence that ligand chemistry, not the element alone, drives the allergy.

DNA binding (platinum drugs)

Cisplatin and its successors lose their leaving groups inside cells and bind DNA, forming crosslinks that block replication. That is how they kill dividing cancer cells, and part of why they also damage the kidney, inner ear and nerves.

Surface catalysis and ion release (nanoparticles)

Metallic platinum surfaces catalyze reactions. In solution, small particles decompose hydrogen peroxide and superoxide, which is the source of the "nanozyme" and antioxidant claims. The same particles can shed platinum ions: Gehrke and colleagues (2011) detected soluble platinum species in culture medium and attributed DNA strand breaks in human colon cells to those ions. Catalysis can also run the other way. When Saitoh and colleagues (Free Radical Research, 2016 and 2021) combined platinum nanocolloid with hydrogen-dissolved water, the mixture generated hydrogen peroxide and raised intracellular reactive oxygen species about 200-fold in a human gastric cancer cell line. A particle that is described as an antioxidant on a label behaved as an oxidant source under those conditions.

Synergistic Supplements

None. No supplement has been shown to make platinum safer or more useful, and no combination product has human data.

Combinations that appear in the literature or on shelves

• Platinum with palladium (PAPLAL). Studied mainly on skin. Shibuya and colleagues reported in 2019 that the mixture did not induce palladium allergy in a mouse model or in human patch tests.

• Platinum nanocolloid with hydrogen-dissolved water. Proposed by the Hiroshima group as an anticancer combination; in cell culture it produced hydrogen peroxide rather than removing it (Section 15). A combination that works by raising oxidative stress in cells is the opposite of what an antioxidant label promises.

Interactions & What NOT to Take

Platinum chemotherapy (cisplatin, carboplatin, oxaliplatin)

• Do not add any platinum colloid during platinum chemotherapy. Isoda and colleagues (2017) found that mice injected with 1 nanometer platinum particles together with cisplatin had worse toxicity than with cisplatin alone, while 8 nanometer particles did not have that effect. No human data exist either way.

• Cisplatin's US label names aminoglycoside antibiotics as potentiating its cumulative kidney toxicity, and aminoglycosides, vancomycin and other ototoxic drugs as adding to its hearing damage.

• The same label warns that plasma levels of anticonvulsants may become subtherapeutic during cisplatin therapy, and that in one randomized ovarian cancer trial pyridoxine (vitamin B6) given with altretamine and cisplatin adversely affected response duration.

Smoking

Tobacco is the most consistently documented modifier of platinum salt allergy. Smokers had about eight times the sensitization risk of non-smokers in Calverley's refinery cohort, and a relative risk of 3.9 in Merget's catalyst cohort. Heederik and colleagues (Journal of Allergy and Clinical Immunology, 2016), analyzing more than 1,000 new refinery workers, found the exposure and sensitization relationship was modified by smoking and atopy.

Other precious metal salts

Hunter's 1945 report found that complex salts of other precious metals, including palladium, did not produce the syndrome in the men studied.

Drug interactions of colloidal platinum

None has been studied in humans. The absence of a recorded interaction for a product that has never been trialed is not evidence of safety.

Quality, Testing & Adulteration

What is actually sold

• MesoPlatinum (Purest Colloids, Inc., USA), a US colloid marketed for drinking. Third-party nanoproduct databases describe it as platinum nanoparticles in deionized water with no other ingredients, alongside manufacturer claims about mental focus, DNA repair and tissue "regeneration." This issue could not check those descriptions against the current label.

• Crystal Colloidals, a European seller of colloidal platinum. Retail listings for its platinum colloid describe it as for external use and not a food or dietary supplement; this issue could not check that wording against the bottle.

What third-party testing covers

USP verification, NSF certification and ConsumerLab testing check identity, content and contaminants against defined standards. This issue found no USP monograph and no NSF or ConsumerLab certification program for colloidal platinum, and no published independent analysis of a US retail platinum colloid. The closest relevant analytical work is academic: the studies in Section 4 show that size, coating and dissolved ion content determine toxicity, and none of those parameters is required on a supplement label.

What a useful certificate of analysis would report

• Total platinum by ICP-MS, in mg per liter, with the method and its limit of quantification.

• Dissolved (ionic) platinum separately from particulate platinum, after ultrafiltration.

• Particle size distribution by transmission electron microscopy or dynamic light scattering, not a single "average."

• The stabilizer or coating, if any. The laboratory colloids cited in this issue used coatings including polyvinylpyrrolidone (PVP), polyvinyl alcohol, citrate, pectin and PEG-lipid, and each coating changes how particles behave.

• Residual synthesis precursors. Platinum particles are typically made by chemically reducing a platinum salt; Park and colleagues (2010), for example, made theirs from potassium hexachloroplatinate. For this element the precursor is a known respiratory sensitizer, so its residual level matters.

• Heavy metal and microbial limits for the water itself.

What you can check on your own

• Whether the product is sold as a food or dietary supplement at all, or carries "not for internal use" language, as the Crystal Colloidals listings describe.

• Whether the percentage and the ppm on the same label agree (1 percent equals 10,000 ppm).

• Whether the seller can name the particle size, the stabilizer and the ionic fraction. A seller who cannot does not know what is in the bottle.

• Whether any claim names a disease or body function. Claims of DNA repair or tissue regeneration are not supported by any human study of platinum colloids.

Special Considerations

Regulatory status

In the EU, platinum cannot legally be added to a food supplement as a mineral, because it is not on the Annex I list of Directive 2002/46/EC. In the US, no FDA monograph, standard of identity or recommended intake exists for platinum in food. This issue found no FDA warning letter or FTC action aimed specifically at colloidal platinum, which says something about enforcement priorities, not about product safety.

Refinery, catalyst and pharmaceutical workers

This is the group for whom platinum is a genuine health issue. Smit and colleagues' exposure study (2023) modeled 2,982 personal air samples from five refineries in the UK, the US and South Africa over 2000 to 2016 and found a geometric mean exposure of 92 nanograms per cubic meter, with facility means from 48 to 242. That overall mean sits above the median 53 nanograms per cubic meter at which sensitization occurred in the group's 2025 analysis, whose authors conclude that the 2,000 nanogram limit does not adequately prevent sensitization and should be reevaluated.

Cancer patients and survivors

People who have had platinum chemotherapy can carry lasting effects: cisplatin's label warns its neuropathies may be irreversible, and in MOSAIC 1.1 percent of oxaliplatin patients still had grade 3 sensory neuropathy a year after treatment. Carboplatin allergy appears mostly in heavily pretreated patients. A platinum colloid adds nothing therapeutic and introduces an untested exposure.

People with dental alloys or implants

Precious-metal dental work raises urinary platinum several-fold, and silicone breast implants contain trace metallic platinum. FDA considers the implant platinum low risk. Neither is a reason to remove dental work or implants, and neither is a reason to add more platinum.

Pets

No veterinary evidence supports giving platinum colloids to animals, and the rodent and zebrafish toxicity findings in this issue argue against it.

Research Status & Evidence Quality

Strong evidence (multiple human cohorts, consistent findings)

• Complex halogenated platinum salts cause respiratory and skin sensitization in exposed workers, from Hunter (1945) and Roberts (1951) through prospective cohorts by Calverley (1995) and Merget (2000). The Utrecht group's retrospective cohorts (2016, 2025) added a quantitative exposure and response relationship.

• Smoking raises sensitization risk severalfold.

• Platinum salt asthma often persists after exposure ends (Merget 1994, 1999, 2016).

• Platinum drugs carry dose-related kidney, ear, nerve and marrow toxicity and cumulative hypersensitivity risk.

Moderate evidence

• Compound speciation determines allergenicity: tetraammine platinum dichloride did not sensitize at comparable exposures (Linnett and Hughes, one company's 20-year dataset).

• Metallic platinum is poorly absorbed and essentially non-allergenic (EHC 125, CDC).

Preliminary or animal-only evidence

• Antioxidant, anti-inflammatory and lifespan effects of platinum nanoparticles: test tube, nematodes and mice.

• Toxicity of platinum nanoparticles: size-dependent kidney and liver injury, cardiac conduction block, gut dysbiosis, DNA damage, all in animals or cells.

No evidence

• Any benefit of drinking colloidal, nano, "mesoplatinum" or "monatomic" platinum in humans.

• Human pharmacokinetics of any retail platinum colloid.

Research Limitations

The occupational cohorts measured inhaled salts, not swallowed particles, so they establish a hazard for one route and form and cannot be stretched to quantify risk from a colloid. The nanoparticle studies used laboratory particles of known size and coating, mostly by injection, at doses chosen for effect, not to mimic a retail product. Several of the positive antioxidant papers come from a small number of groups. The 2025 Utrecht analysis was retrospective and used modeled rather than individually measured exposures, a limitation the authors acknowledge. This issue found no study of the kind that would settle the supplement question: a controlled trial measuring absorption, kidney markers and sensitization in people drinking a characterized platinum colloid.

Summary & Key Takeaways

Bottom Line

Platinum's human record is an occupational one. Its chlorinated salts sensitize workers' airways at concentrations far below the legal limit, and the resulting asthma often outlasts the job. The metal itself is close to inert and barely absorbed. The colloidal and nano platinum sold for drinking sits between those two facts with no human trial, no particle-size standard, no requirement to disclose dissolved platinum, and laboratory data showing that small platinum particles can shed ions, damage DNA in cells and injure the kidneys of injected mice.

Key Safety Points

• Do not drink platinum colloids, "mesoplatinum," "monatomic" platinum or platinum water.

• Do not combine any platinum product with cisplatin, carboplatin or oxaliplatin.

• Anyone working with chloroplatinates should be in skin prick test surveillance and should not smoke.

• New rhinitis, wheeze, hives or kidney test changes after using a platinum product warrant stopping it and telling a clinician.

• "Platinum" on a label says nothing about the chemical form, particle size or ionic content that decide toxicity.

Special Note

If you have already been drinking a platinum colloid, no validated test can tell you what it did. A urine platinum result can be compared with the German reference value of 10 nanograms per liter for adults without precious-metal dental work, but that figure describes background exposure, not harm, and serum platinum failed to predict sensitization even in exposed workers. The practical steps are to stop, keep the bottle and label for your clinician, and, after months of use, ask whether routine kidney function tests (creatinine and eGFR) make sense for you.

Forwarded this, or reading it on the web? to get the next breakdown.

Researched and drafted with AI assistance. Every claim verified against primary sources and human-reviewed before publication. Last reviewed: November 2, 2026. Corrections: reply to any issue.

This issue is for education only and is not medical advice. If you take any medication, are being treated for cancer, work with platinum compounds, or have a diagnosed condition, talk with a clinician before starting, stopping or changing anything.